Statins for primary prevention of cardiovascular disease in Germany: benefits and costs
The reduction of LDL cholesterol lowers the risk of coronary and cerebrovascular events in individuals without manifest cardiovascular diseases. In Germany, statins at the expense of statutory health insurance had only been permitted for patients with atherosclerosis-related diseases or those at hig...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
17 March 2025
|
| In: |
Clinical research in cardiology
Year: 2025, Pages: 1-14 |
| ISSN: | 1861-0692 |
| DOI: | 10.1007/s00392-025-02608-5 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s00392-025-02608-5 Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1007/s00392-025-02608-5 
|
| Verfasserangaben: | Alexander Dressel, Felix Fath, Bernhard K. Krämer, Gerald Klose, Winfried März |
| Zusammenfassung: | The reduction of LDL cholesterol lowers the risk of coronary and cerebrovascular events in individuals without manifest cardiovascular diseases. In Germany, statins at the expense of statutory health insurance had only been permitted for patients with atherosclerosis-related diseases or those at high cardiovascular risk (over 20 percent event probability within the next 10 years, calculated using one of the “available risk calculators”). However, international guidelines recommend lower risk thresholds for the use of statins. |
|---|---|
| Beschreibung: | Gesehen am 23.07.2025 |
| Beschreibung: | Online Resource |
| ISSN: | 1861-0692 |
| DOI: | 10.1007/s00392-025-02608-5 |